Legacy Education (LGCY) closed fiscal 2026 with a quarter that looks cleaner on the income statement than in the operating details. For the fiscal fourth quarter ended June, the company earned $0.13 per diluted share, up 44.4% from a year earlier. Revenue rose 12.0% to $20.1 million, 1.8% above the $19.74 million consensus. Full-year revenue climbed 24.8% to a record $80.1 million, and diluted EPS rose to $0.66 from $0.59. The central tension is that profitability is improving just as the engine behind future revenue, new student starts, has stalled. The quarter delivered margin leverage, but the growth story is losing altitude.
The quality of the earnings beat deserves scrutiny. Operating income rose to $2.6 million from $2.0 million, and operating margin expanded 190 basis points to 13.0%. Adjusted EBITDA grew to $3.1 million, a 15.5% margin versus 13.3% a year ago. But much of the 53.3% jump in net income came from below the operating line. Tax expense fell to $0.7 million from $1.0 million, and pretax income grew far more modestly, to $2.59 million from $2.25 million. The mix of margin improvement is also telling. General and administrative expense declined year over year to $5.9 million. Educational services expense, however, rose to 56.0% of revenue from 52.6% as capacity spending at expanded campuses ran ahead of enrollment. Cash conversion is a legitimate concern. Fiscal 2026 operating cash flow was only $4.0 million against $9.1 million of net income, as net receivables swelled to $19.9 million.
The call made the deceleration hard to ignore. Year-over-year revenue growth went from 38.5% and 40.7% in the first two quarters to 15% in Q3 and 12% in Q4 as the Contra Costa acquisition annualized. Revenue also slipped sequentially, from $21.4 million in Q3 to $20.1 million. Pre-existing brands grew 11.3% in Q4, which is respectable organic growth. The leading indicator is weaker. Starts swung from gains of roughly 32% and 49% in the first half to declines of about 12% in Q3 and about 4% in Q4. Ending population growth slowed to 8.9%, at 3,377 students. Management expects the September quarter to look similar to June before improving. It cited three causes:
- tighter vocational nursing entrance requirements;
- a slipped surgical technology rollout at a third High Desert campus, tied to lab and equipment readiness;
- a sterile processing program that is still ramping.
Adjusted EBITDA of $3.1 million was also well below Q3's $4.4 million, which came at a 20.6% margin.
The forward catalysts are real but back-end loaded. Legacy converted its Q3 letter of intent into an executed 28,000-square-foot lease for a Houston branch, its first campus outside California. The campus targets a November 2026 opening, pending regulatory and accreditation approvals. Management estimates 400-600 students there within one to two years and framed Texas as a potential statewide opportunity. Contra Costa added approvals for MRI and cardiac sonography associate degrees and a veterinary assistant certificate, and two schools earned maximum-term reaccreditations. The CFO expects margins to keep expanding in fiscal 2027, mostly in the second half. The credibility ledger took a hit, though. Management had targeted an acquisition announcement within fiscal 2026 and in Q3 described a deal as 'close.' None materialized, and the call offered only that targets are 'actively under review,' with no timing. The balance sheet leaves room to act: $22.7 million of cash, $33.4 million of working capital, and no debt facility. Execution, not capacity, is the open question.
Investors appeared to sense trouble going in. Earnings Whispers sentiment swung from roughly neutral at 0.05 after the prior report to a clearly negative -0.47 ahead of this release, a substantial deterioration. The stock tells a similar story. At $10.31, shares are down 9.6% since the open after the May report and sit about 9.9% below the 200-day moving average of $11.44. They also trade just 3.1% above the inter-earnings low of $10.00 set in mid-August, after fading 18% from a late-July high of $12.60. Price and AVWAP trend readings are negative, consistent with a market that has been selling rallies.
The bottom line is that Legacy delivered a margin-led beat and a record year, but the report shifts the debate from how fast the company is growing to when growth resumes. Two straight quarters of declining starts, guidance for another soft September quarter, and a missed acquisition timeline give bears legitimate ammunition. Houston, new program approvals, and second-half margin guidance keep a credible expansion narrative intact, but those payoffs sit largely in calendar 2027. Until starts turn positive and cash conversion improves, the stock's depressed technical position and sour sentiment look more like a rational discount than an overreaction.